Tag Archives: P-BCMA-101

Poseida to Prioritize P-BCMA-ALLO1 Over P-BCMA-101; Program Updates for P-PSMA-101 and P-MUC1C-ALLO1; Poseida Q3 2021 Earnings Summary

On Tuesday, November 9, Poseida Therapeutics released their Q3 2021 financial results (press release) highlighting their strategic shift towards allogeneic CAR-Ts for their BCMA program. Additionally, management provided further updates on their PSMA and MUC1 candidates. Below, Celltelligence provides insights on Poseida’s overarching strategy to prioritize their allogeneic BCMA and PSMA therapies while discussing their MUC1-targeting approach.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on Poseida’s Strategies to Improve Allogeneic CAR-T Manufacturing and Efficacy; Clinical Development Updates and New Cell Therapy Platforms; Poseida’s First R&D Day Summary

On Wednesday, February 24, Poseida Therapeutics held their first R&D day (presentation). Management presented a novel booster molecule to improve allogeneic manufacturing and discussed their approach to developing next-generation technologies. Below, Celltelligence provides insights on how Poseida’s allogeneic improvements could significantly decrease manufacturing costs, while discussing Poseida’s development of CAR-T therapies from different cell sources.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.